Medical Technology Firm Brainlab to Go Public on Frankfurt Stock Exchange

The Munich-based medical technology company Brainlab is set to launch its initial public offering (IPO) on the Frankfurt Stock Exchange.

According to an announcement made by the company on Thursday, Brainlab plans to list on the regulated market (Prime Standard) in the coming weeks. Through the issuance of new shares, the firm aims to raise up to €200 million, which will be used to expand its business operations. The primary focus will be on broadening the company’s software offerings to additional clinical applications and adjacent market segments, as well as strengthening its balance sheet. Additionally, current shareholders intend to sell part of their holdings to ensure sufficient free float. The IPO is being organized by Berenberg, Deutsche Bank, Commerzbank, Jefferies, and Unicredit, with Evercore providing advisory services to the company.

Brainlab, which employs around 2,000 people, offers medical technology software for procedures such as surgeries and tumor radiation therapies. The company was founded 35 years ago by Stefan Vilsmeier, who announced his withdrawal from day-to-day operations just over six months ago. Vilsmeier will continue to support Brainlab as a long-term investor, the company stated. In the first half of the year, Brainlab reported revenues of €239 million and an operating profit margin of 22.4 percent.

(Reporting by Christina Amann, edited by Myria Mildenberger. For questions, please contact our editorial team at [e-mail] (for politics and economy) or [e-mail] (for companies and markets).